Together, those observations suggest that treating breast cancer patients with Dasatinib (pan-SFK) could have the unanticipated consequence of promoting breast cancer liver metastasis formation whereas breast cancer patients may benefit from Bafetinib (Lyn-selective) treatment. This evidence concerns the gene LYN and breast cancer.